Related Experiment Video
Updated: Jan 26, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials
Ilaria Dicembrini1, Besmir Nreu1, Edoardo Mannucci1
1Department of Diabetology, Careggi Teaching Hospital, University of Florence, Florence, Italy.
Aim:
The aim of this meta-analysis of randomized trials was to assess the effects of SGLT-2i on the overall incidence of malignancies and on different types of cancer, summerizing the results of trials with a duration of at least 1 year. This was done in light of the effect of SGLT-2 inhibitors (SGLT-2is) that has been highlighted by some studies, showing an increased incidence of bladder cancer, particularly with use of empagliflozin.
Materials And Methods:
A Medline and Embase search for "Canaglifozin", "Dapaglifozin", "Empaglifozin", "Ertuglifozin", "Ipraglifozin", Tofoglifozin" or "Luseoglifozin" was performed, identifying randomized trials with a duration of more than 52 weeks up to 1 December 2018 that compared SGLT-2is with placebo or active comparators. The outcomes considered were all types of cancer and several site-specific cancers (ie, breast, pulmonary, gastrointestinal, hepatic, pancreatic, skin, prostate and bladder). Mantel-Haenszel odds ratios with 95% Confidence Intervals (MH-OR, 95% CI) were calculated for all outcomes.
Results:
A total of 27 trials fulfilled the inclusion criteria. Retrieved trials had enrolled 27 744 and 20 441 patients in SGLT-2 inhibitor and comparator groups, respectively. No difference was observed in the incidence of all malignancies between patients allocated to SGLT-2i and comparators (MH-OR 0.98[0.77-1.24]). The incidence of bladder cancer, and of any other type of cancer, was not significantly increased by treatment with any SGLT-2i.
Conclusions:
Available data from randomized trials do not suggest a detrimental effect of SGLT-2is on the incidence of malignancies in general, or in bladder cancer in particular.
Insights
Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) do not increase the overall incidence of malignancies or specific cancers like bladder cancer. This meta-analysis of randomized trials found no detrimental effect of SGLT-2is on cancer risk.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Some studies suggested a potential increased risk of bladder cancer with SGLT-2 inhibitors, particularly empagliflozin.
- This prompted an investigation into the overall and specific cancer incidence associated with SGLT-2 inhibitor use.
Purpose of the Study:
- To conduct a meta-analysis of randomized trials to assess the effect of SGLT-2 inhibitors (SGLT-2is) on the overall incidence of malignancies.
- To evaluate the impact of SGLT-2is on various site-specific cancers, including bladder cancer.
Main Methods:
- A systematic search of Medline and Embase was performed for randomized trials of SGLT-2is (canagliflozin, dapagliflozin, empagliflozin, etc.) published up to December 1, 2018.
- Trials with a duration exceeding 52 weeks, comparing SGLT-2is to placebo or active comparators, were included. Outcomes included all cancer types and site-specific cancers.
- Mantel-Haenszel odds ratios (MH-OR) with 95% Confidence Intervals (CI) were calculated.
Main Results:
- Twenty-seven trials with 27,944 patients in the SGLT-2 inhibitor group and 20,441 in the comparator group met the inclusion criteria.
- No significant difference in the incidence of all malignancies was observed between SGLT-2i and comparator groups (MH-OR 0.98 [0.77-1.24]).
- The incidence of bladder cancer and other specific cancer types was not significantly increased with SGLT-2i treatment.
Conclusions:
- Current data from randomized trials do not indicate an increased risk of malignancies with SGLT-2 inhibitor use.
- SGLT-2 inhibitors do not appear to have a detrimental effect on the incidence of bladder cancer or other cancers.
Related Concept Videos
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
2° Amines to N-Nitrosamines: Reaction with NaNO2
Secondary Active Transport
SN2 Reaction: Kinetics
In a chemical reaction, a relationship exists between the concentration of reactants and the rate at which the reaction proceeds. The study to measure this relationship is known as the kinetics of a chemical reaction. Kinetic studies are used to deduce the rate law of a chemical reaction, which provides information about the species involved during the transition state of the rate-determining step. Thus, kinetic studies help to derive the mechanism of a...
SN2 Reaction: Mechanism
The presence of the more electronegative halogen in the substrate creates a polarized carbon-halide bond. The halide pulls the electron cloud generating an electrophilic center at the carbon atom. Thus, the carbon atom carries a partial positive charge while the halide has a...

